Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

(Eds: With file pics) Hyderabad, Two major vaccine makers from Hyderabad, <keyword id="1379126" type="General" weightage="20" keywordseo="Biological-E" source="Orion">Biological E</keyword> Ltd and <keyword id="149108" type="General" weightage="100" keywordseo="bharat-biotech" source="Orion">Bharat Biotech</keyword>, together are holding about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. According to respective company sources, Biological E is holding 200 million doses of its COVID-19 vaccine <keyword id="11370342" type="General" weightage="80" keywordseo="corbevax" source="Orion">Corbevax</keyword> while Bharat Biotech is sitting on a stockpile of 50 million doses of Covaxin. Dr Vikram Paradkar, Executive Vice President (Manufacturing), Biological E, said the firm produced about 30 crore doses of Corbevax in total, abiding by the vaccine manufacturing commitment to the Central government. In March '22, Biological E successfully supplied 10 crore doses to the government. "Currently, we have approximately 20 crore (200 million) doses that are fully tested and ready for supply, as and when we receive orders. Additionally, we manufactured 20 crore doses equivalent of the antigen which will help us ramp up the manufacturing of the Corbevax finished product quickly," Paradkar told PTI. The vaccine has been developed by Biological E in collaboration with Texas Children's Hospital Center for Vaccine Development (Texas Children's CVD) and Baylor College of Medicine (Baylor) in Houston, Texas, USA. He further said Biological E can begin with the additional vaccine supplies within eight weeks of future orders and can manufacture and supply approximately 10 crore doses of Corbevax on a monthly basis as per its qualified manufacturing capacity. Bharat Biotech sources said the vaccine maker has more than 50 million doses of Covaxin readily available in vials, and over 200 million doses as drug substance. "Additional production capacity is also available to meet product demand," they said adding fresh stocks of the vaccine are available and ready for supplies. Covaxin, India's indigenous COVID-19 vaccine, was developed in collaboration with the <keyword id="6364555" type="General" weightage="50" keywordseo="indian-council-of-medical-research" source="Orion">Indian Council of Medical Research</keyword> (ICMR) - National Institute of Virology (NIV). Due to lack of product demand, production stoppage of Covaxin was initiated earlier this year and also the 50 million doses in vials are set to expire during early 2023, resulting in losses to the company, sources had earlier said. SEE ALSO: <a href="https://www.businessinsider.in/india/news/rise-in-active-covid-19-cases-in-bihar-no-need-for-panic-says-expert/articleshow/96561025.cms">Rise in active COVID-19 cases in Bihar; no need for panic, says expert</a> <a href="https://www.businessinsider.in/science/health/news/covid-19-nasal-vaccine-bharat-biotechs-incovacc-is-the-first-approved-intranasal-vaccine-in-the-world/slidelist/96542239.cms">All you need to know about the world’s first Covid-19 nasal vaccine - iNCOVACC</a>

Biological E, Bharat Biotech together sitting on stockpile of 250 million COVID vaccine doses

Vaccination for 12-14 year olds starts from tomorrow — registration, dosage gap and cost

<keyword id="1379126" type="General" weightage="20" keywordseo="Biological-E" source="Orion">Biological E</keyword>. Limited, whose <keyword id="11370342" type="General" weightage="100" keywordseo="corbevax" source="Orion">Corbevax</keyword> on Tuesday received the approval from the Drugs Controller General of India (DGCI), plans to produce 75 million doses per month and anticipates over 100 million doses per month from February 2022. The Hyderabad-based company said these capacities will enable it to deliver 300 million doses as promised to the Government of India. Soon, the company plans to deliver more than one billion additional doses globally. Corbevax, India's first indigenously developed protein sub-unit vaccine against Covid-19, has been developed by Biological E in collaboration with Texas Children's Hospital Center for Vaccine Development (Texas Children's CVD) and Baylor College of Medicine (Baylor) in Houston, Texas. The vaccine will be effective both in scale and affordability, providing sustainable access to low-and middle-income countries, the vaccine maker said. "Our scientists at Texas Children's Hospital and Baylor College of Medicine are thrilled to help in the development of this vaccine, possibly the first Covid vaccine specifically designed for global health," said Dr. Peter Hotez, professor and dean of the National School of Tropical Medicine at Baylor and co-director of the Texas Children's Hospital Centre for Vaccine Development. "Over the years, we have worked to make quality vaccines and pharmaceutical products accessible to families around the world. With this as our backdrop, we resolved to develop an affordable and effective Covid-19 vaccine. It has now become a reality," said Mahima Datla, Managing Director, Biological E. Limited. Corbevax has completed two Phase III clinical trials involving more than 3,000 subjects between the ages of 18 and 80 at 33 study sites across India. The vaccine was found to be safe, well tolerated and immunogenic. Corbevax is a "recombinant protein sub-unit" vaccine, developed from the receptor binding domain (RBD) of the spike protein on the virus's surface combined with Dynavax's CpG 1018 adjuvant with alum, which helps the body build the immune response against the virus. "In the pivotal Phase III study conducted with an endpoint of immunogenic superiority, Corbevax demonstrated superior immune response in comparison with Covishield vaccine when assessed for Neutralising Antibody (nAb) Geometric Mean Titers (GMT) against the Ancestral-Wuhan strain and the globally dominant Delta variant. Corbevax vaccination also generated a significant Th1 skewed cellular immune response," Biological E said. According to the vaccine-maker, Corbevax nAb GMT against Ancestral-Wuhan strain is indicative of vaccine effectiveness of more than 90 per cent for prevention of symptomatic infections based on the Correlates of Protection assessment performed during Moderna and Astra-Zeneca vaccine Phase III studies. Against the Delta strain, it indicates a vaccine effectiveness of more than 80 per cent for the prevention of symptomatic infections based on published studies. While none of the subjects who took Corbevax or Covishield had serious adverse events, Corbevax had 50 per cent fewer adverse events than Covishield. SEE ALSO: <a href="https://www.businessinsider.in/india/news/govt-panel-allows-emergency-use-of-mercks-new-drug-molnupiravir-for-treatment-of-mild-to-moderate-covid-19-cases/articleshow/88536179.cms">India allows emergency use of Merck's new drug Molnupiravir for treatment of mild-to-moderate COVID-19 cases</a>

Biological E to produce 100 million doses of Corbevax Covid vaccine from February 2022

<ul><li>The government of India has approved a second COVID-19 <keyword id="7566322" type="General" weightage="20" keywordseo="vaccine-for-kids" source="Orion">vaccine for kids</keyword>.</li><li>The government would accept school ID cards for the vaccination of kids.</li><li>Now kids over 12 years of age can get themselves registered for COVID-19 vaccination.</li></ul>Disclaimer: This article should not be taken as medical advice. The government of India has approved a second <keyword id="8904563" type="General" weightage="20" keywordseo="covid-19-vaccine" source="Orion">COVID-19 vaccine</keyword> for kids, nearly a month after officially launching the vaccination drive for teens between the age of 15-18. This move will enable kids over 12 years of age vaccinated against COVID-19. The government would accept school ID cards for the vaccination of kids, therefore, kids without an Aadhaar Card will also be able to get vaccinated. This comes off as a sign of relief for parents who were getting anxious about the delay in getting their kids vaccinated. Adolescents can apply for the vaccination dose on the CoWin app. But before taking your kids for vaccination, these are the things you need to know. <keyword id="9507941" type="General" weightage="20" keywordseo="zycov-d" source="Orion">ZyCoV-D</keyword> is needle-free Age group: 15-18 Zydus’ vaccine ZyCov-D was the first COVID-19 vaccine — fifth vaccine overall — to be approved in India for kids. The vaccine was available for teens between the age of 15-18, starting from January 3, 2022. Unlike other vaccines, ZyCov-D is needle-free. It is injected through a needle-free applicator called PharmaJet that uses a narrow stream of the fluid to penetrate the skin and deliver the jab. This is also a plasmid — a type of DNA found mostly in bacteria — which provides the spike protein of the SARS-CoV-2 virus and elicits an immune response mediated by the cellular and humoral arms of the human immune system. “The Plasmid DNA platform also allows generating new constructs quickly to deal with mutations in the virus, such as those already occurring,” Cadila Healthcare, the manufacturer of the vaccine, had told the government in August 2021. <keyword id="11370342" type="General" weightage="20" keywordseo="corbevax" source="Orion">Corbevax</keyword> is a protein sub-unit COVID-19 vaccine Age Group: 12-18 Corbevax is India’s first indigenously developed protein sub-unit COVID-19 vaccine, which includes parts of a virus that stimulates an immune system. "CORBEVAX is a “recombinant protein sub-unit” vaccine, developed from a component of the spike protein on the virus’s surface, which helps the body build the immune response against the virus,” Biological E Limited, the manufacturer of the vaccine, explained. The vaccine has been developed by Biological E Limited in collaboration with Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD) and Baylor College of Medicine (Baylor) in Houston, Texas. SEE ALSO <a class="tout-title-link" href="https://www.businessinsider.in/stock-market/news/vedanta-reliance-airtel-and-other-hot-stocks-on-february-22-as-russia-ukraine-crisis-spooks-global-markets/slidelist/89737976.cms">Vedanta, Reliance, Airtel and other hot stocks on February 22 as Russia-Ukraine crisis spooks global markets</a> <a href="https://www.businessinsider.in/politics/world/news/putin-orders-russian-troops-to-eastern-ukraine-for-peacekeeping-operation-a-major-escalation-towards-a-war/articleshow/89735923.cms" data-type="tilCustomLink">Putin orders Russian troops to eastern Ukraine for 'peacekeeping' operation, a major escalation towards a war</a> <a href="https://www.businessinsider.in/entertainment/news/fans-mourn-the-end-of-arthur-after-25-years-of-life-lessons-and-a-bunch-of-iconic-memes/articleshow/89737181.cms" data-type="tilCustomLink">Fans mourn the end of 'Arthur' after 25 years of life lessons and a bunch of iconic memes</a>

Corbevax and ZyCoV-D – Things to keep in mind before taking your kids for COVID-19 vaccination

<ul><li><keyword id="6672294" type="General" weightage="20" keywordseo="reliance-life-sciences" source="Orion">Reliance Life Sciences</keyword> has reportedly approached India’s drug regulator, seeking permission for trials of its vaccine.</li><li>The subject expert committee (SEC) is said to have reviewed its application yesterday and gave its approval.</li><li>Phase-1 of the trial usually lasts for 58 days to determine the highest dose that most patients can tolerate.</li></ul>Indian pharma firm Reliance Life Sciences on Thursday, August 26, reportedly received regulatory approval to conduct clinical trials of its <keyword id="8904563" type="General" weightage="20" keywordseo="covid-19-vaccine" source="Orion">COVID-19 vaccine</keyword> candidate. The company — run by India’s richest man <keyword id="3820" type="General" weightage="20" keywordseo="mukesh-ambani" source="Orion">Mukesh Ambani</keyword> — has reportedly approached India’s drug regulator, seeking permission to start Phase-1 trials for its proposed two-dose vaccine, according to a <a href="https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/reliance-life-gets-regulatory-nod-for-trials-of-2-dose-vax/articleshow/85669453.cms">report</a> by The Economic Times (ET), which quoted sources it did not name. The subject expert committee (SEC) is said to have reviewed its application on Thursday and has given its approval. Reliance Life Sciences aims to obtain reliable information on safety, tolerability, how it reacts with living organisms (pharmacokinetics or PK) and mechanism of action of the drug. The company aims to determine the maximum tolerated dose (MTD) with these trials. Business Insider has reached out to Reliance Life Sciences seeking more details about their vaccine and Phase-1 trials. A person aware of the development told the publication that Phase-1 of the trial usually lasts for 58 days to determine the highest dose that most patients can tolerate. The company will be able to conduct phase two or three of the vaccine only after phase one is completed, the person told ET. The vaccine by Reliance Life Sciences will be a recombinant protein vaccine, similar to the Corbevax vaccine developed by Hyderabad-based Biological E. Biological E is expected to <a href="https://www.hindustantimes.com/india-news/biological-e-s-covid-19-vaccine-likely-to-be-launched-in-september-report-101627294911918.html">apply</a> for an emergency use authorisation (EUA), which allows temporary use of a medicine under specific conditions. So far, six vaccines have received EUA in India. This includes Zydus Cadila’s vaccine, Serum Institute of India’s <keyword id="9617748" type="General" weightage="20" keywordseo="covishield" source="Orion">Covishield</keyword>, Bharat Biotech’s <keyword id="9485939" type="General" weightage="20" keywordseo="covaxin" source="Orion">Covaxin</keyword>, Russia’s Sputnik V, Moderna and Johnson &amp; Johnson. Drugs Controller General of India (DCGI) had approved <a href="https://www.businessinsider.in/science/health/news/cadila-healthcare-to-launch-zycov-d-vaccine-for-12-year-old-and-above/articleshow/85564761.cms">Cadila Healthcare’s ZyCoV-D </a>COVID-19 vaccine for emergency use, earlier this week. ZyCoV-D vaccine is also suitable for the younger population above 12 years of age. Adding to it, the vaccine is needle-free unlike other vaccines. The company plans to manufacture 10-12 crore doses of ZyCoV-D annually and is expected to be made available in September in India. SEE ALSO <a href="https://www.businessinsider.in/stock-market/news/infosys-wipro-adani-green-and-other-top-stocks-to-watch-out-for-on-august-27/slidelist/85676193.cms">Infosys, Wipro, Adani Green and other top stocks to watch out for on August 27</a> <a href="https://www.businessinsider.in/business/startups/news/google-backed-dunzo-earned-nearly-600-crore-from-8-cities-in-fy21-ceo-says-theyll-start-expanding-now/articleshow/85656919.cms">Google-backed Dunzo earned nearly ₹600 crore from 8 cities in FY21, CEO says they'll start expanding now</a> <a href="https://www.businessinsider.in/tech/enterprise/news/amazon-twitter-hyundai-and-dominos-are-buying-indian-software-fuelling-a-75-billion-dream-chased-by-top-vcs-like-sequoia-and-tiger-global/articleshow/85646116.cms">Amazon, Twitter, Hyundai, and Domino’s are buying Indian software fuelling a $75 billion dream chased by top VCs like Sequoia and Tiger Global</a>

Mukesh Ambani-owned Reliance Life Sciences' COVID-19 vaccine — here's all we know so far

<keyword id="6358777" type="General" weightage="20" keywordseo="new-delhi" source="Orion">New Delhi</keyword>, March 14 (IANS) The <keyword id="6362177" type="General" weightage="20" keywordseo="union-government" source="Orion">Union Government</keyword> after deliberations with scientific bodies decided on Monday to start <keyword id="9257042" type="General" weightage="20" keywordseo="covid-vaccination" source="Orion">Covid vaccination</keyword> for 12-14 year age group from March 16. Those teenagers born in 2008, 2009 and 2010 or those who are already above 12 years of age of population will be administered <keyword id="8764262" type="General" weightage="100" keywordseo="covid" source="Orion">Covid</keyword> vaccines from March 16. The Covid-19 vaccine to be administered would be Corbevax manufactured by Hyderabad based Biological E, said the <keyword id="83655" type="General" weightage="20" keywordseo="union-health-ministry" source="Orion">Union Health Ministry</keyword>. The government has also decided that the condition of co-morbidity for Covid-19 precaution dose for population over 60 years of age will be removed forthwith. "If children are safe then the country is safe! I am happy to inform that the Covid vaccination program for the children in the age group of 12 to 13 and 13 to 14 is starting from March 16", said Union Health Minister Mansukh Mandaviya in a tweet. "Also, everyone aged 60 plus will now be able to get precaution dose. I urge the families of children and people in the age group of 60 plus that they must get the vaccine", he said in the same tweet in Hindi. The ministry said that the population above 14 years of age is already being administered vaccines under the ongoing vaccination drive. "Hence, from 16th March 2022 onwards, the entire population above 60 years of age will be eligible for Precaution Dose of COVID19 vaccine", said the ministry. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/politics/india/news/india-records-the-lowest-single-day-covid-19-spike-only-2503-cases-in-680-days/articleshow/90195533.cms">India records the lowest single-day COVID-19 spike, only 2,503 cases in 680 days</a> <a href="https://www.businessinsider.in/stock-market/news/paytms-shares-hit-an-all-time-low-plunging-below-the-700-mark-after-rbi-pulls-up-its-payments-bank/articleshow/90193957.cms">Paytm’s shares hit an all-time low plunging below the ₹700-mark after RBI pulls up its payments bank</a>

India to begin COVID-19 vaccination for kids aged 12 to 14 from Wednesday

<ul class="summary-list"><li>Public health experts have previously said <keyword id="11894310" type="UNKNOWN" weightage="60" keywordseo="vaccine" source="Orion">vaccine</keyword> inequality would allow for new variants. </li><li>A Texas doctor and his team developed Corbevax, a low-cost COVID-19 vaccine. </li></ul>A Texas pediatrician and a professor developed a low-cost COVID-19 vaccine that was approved for emergency use in <keyword id="11892747" type="UNKNOWN" weightage="60" keywordseo="india" source="Orion">India</keyword> on Tuesday. Dr. Peter Hotez, a pediatrician at Texas Children's Hospital, developed the Corbevax vaccine alongside Baylor College professor Dr. Maria Elena Bottazzi, <a href="https://www.texaschildrens.org/texas-children%E2%80%99s-hospital-and-baylor-college-medicine-covid-19-vaccine-technology-secures-emergency">a press release from the children's hospital said. </a>"This announcement is an important first step in vaccinating the world and halting the pandemic," Hotez said. The vaccine, which the developers called the "World's COVID-19 Vaccine," uses a traditional recombinant protein-based technology, which would allow it to be mass-produced and used across the globe. "Protein-based vaccines have been widely used to prevent many other diseases, have proven safety records, and use economies of scale to achieve low-cost scalability across the world," Bottazzi said.According to the press release, the vaccine's initial construct and production was developed at Texas Children's Hospital and then licensed from the Baylor College of Medicine to Biological E. Limited, a Hyderabad-based vaccine, and pharmaceutical company. Hotez said in a <a href="https://twitter.com/PeterHotez/status/1475838570883690499">tweet</a> that Biological E. already has 150 million doses ready and will be making 100 million doses a month. The vaccine was found to be safe and effective after two phase 3 clinical trials of more than 3,000 participants, the press release said. The low-cost vaccine is meant to help<a href="https://www.businessinsider.com/new-coronavirus-variant-may-be-result-of-vaccine-inequality-2021-11"> low and middle-income countries</a>, access vaccines, the press release said. "Widespread and global vaccination with our Texas Children's-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow," Hotez said. The announcement comes as the <a href="https://www.businessinsider.com/how-long-does-booster-protection-omicron-covid-last-study-2021-12">Omicron variant</a> spreads across the globe. The variant is believed to be more transmissible than previous variants. So far, there have been more than 282 million COVID-19 cases across the globe, according to data from Johns Hopkins University. Experts have previously warned that rich countries hoarding vaccines and the lack of access in poorer countries could allow for new variants to emerge. While more than 48% of the world population has been fully vaccinated, wealthier countries <a href="https://ourworldindata.org/covid-vaccinations?country=OWID_WRL">like the US and UK have a significantly higher rate of doses administered per 100 people. </a>Ken Shadlen, a professor of development studies at the London School of Economics and Political <keyword id="11896083" type="UNKNOWN" weightage="100" keywordseo="science" source="Orion">Science</keyword>, <a href="https://www.businessinsider.com/rich-nations-hoarding-covid-19-vaccines-could-backfire-experts-say-2021-3?r=US&amp;IR=T">told Insider's Sinéad Baker</a> in March that if global vaccine inequality persists "it's going to potentially undermine the health benefits of all that we're doing with lockdowns and vaccines."The vaccine's authorization was praised by Texas politicians, including former presidential candidate Beto O'Rourke. "Making Texas proud!" O'Rourke <a href="https://twitter.com/BetoORourke/status/1475909362736631810">said</a> of Hotez's team. <a href="https://t.co/zMnxgBveZz" target="_blank" rel="noopener noreferrer"></a>In a <a href="https://twitter.com/PeterHotez/status/1475839914910666767?s=20">tweet</a>, Hotez added that the children's hospital does not plan to profit from the vaccine, calling it a "gift to the world."He said the technology to develop the vaccine has already been transferred to producers in India, Indonesia, Bangladesh, and Botswana.Hotez did not respond to Insider's request for comment at the time of publication.

A Texas pediatrician and professor developed a low-cost COVID-19 vaccine. India just granted it emergency use authorization.

Sun Pharmaceutical Industries on Tuesday announced that one of its wholly owned subsidiaries has received emergency use authorisation (EUA) from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of <keyword id="66878" type="General" weightage="20" keywordseo="merck" source="Orion">Merck</keyword>'s <keyword id="12826599" type="General" weightage="20" keywordseo="anti-Covid-pill-Molnupiravir" source="Orion">anti-Covid pill Molnupiravir</keyword> in India. <keyword id="44642" type="General" weightage="20" keywordseo="sun-pharma" source="Orion">Sun Pharma</keyword> will launch <keyword id="10880838" type="General" weightage="20" keywordseo="Molnupiravir" source="Orion">Molnupiravir</keyword> under the brand name Molxvir in India, within a week, the company said in a statement. Amid the ongoing resurgence of new Covid-19 cases in India, an expert panel of the Central Drugs Standard Control Organisation on Tuesday approved Merck's anti-viral drug molnupiravir for restricted use in emergency situations. Earlier this year, the Sun Pharma had signed a non-exclusive voluntary licensing agreement with US-based Merck to manufacture and supply a generic version of molnupiravir in over 100 low and middle-income countries (LMICs) including India. The DCGI, based on the review of clinical data of molnupiravir has approved molnupiravir for treatment of adult patients with Covid-19, with oxygen saturation less than 93 per cent and who have high risk of progression of the disease, including hospitalisation or death. "Molnupiravir is an important addition to the portfolio of oral therapies available for treating Covid-19 patients. In line with our consistent efforts to accelerate access to new drugs for Covid-19 treatment, we will make Molxvir available to patients at an affordable price," said Kirti Ganorkar, CEO of India Business, Sun Pharma, in a statement. Ganorkar added that the company is in the process of launching a toll-free helpline to ensure the availability of Molxvir to doctors and patients across India. "Our endeavour is to make the product available in a week's time," she said. The recommended dose of the drug is 800 mg twice a day for five days. The duration of treatment of molnupiravir is much shorter compared to other therapies which is a significant advantage as it reduces the pill burden and enhances compliance. Molnupiravir is an oral anti-viral that inhibits the replication of multiple RNA viruses including SARS-CoV-2. The drug is used for the treatment of non-hospitalised patients with Covid-19 globally. Molnupiravir has been developed by Merck and Ridgeback Biotherapeutics. The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have granted the pill EUA. SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/biological-e-to-produce-100-million-doses-of-corbevax-covid-vaccine-from-february-2022/articleshow/88543250.cms">Biological E to produce 100 million doses of Corbevax Covid vaccine from February 2022</a> <a href="https://www.businessinsider.in/india/news/govt-panel-allows-emergency-use-of-mercks-new-drug-molnupiravir-for-treatment-of-mild-to-moderate-covid-19-cases/articleshow/88536179.cms">India allows emergency use of Merck's new drug Molnupiravir for treatment of mild-to-moderate COVID-19 cases</a>

You Searched For "Corbevax vaccine" and got 8 results

Biological E, Bharat Biotech together sitting on stockpile of 250 million COVID vaccine doses

PTI

Vaccination for 12-14 year olds starts from tomorrow — registration, dosage gap and cost

Kritti Bhalla

Biological E to produce 100 million doses of Corbevax Covid vaccine from February 2022

IANS

Corbevax and ZyCoV-D – Things to keep in mind before taking your kids for COVID-19 vaccination

Kritti Bhalla

Mukesh Ambani-owned Reliance Life Sciences' COVID-19 vaccine — here's all we know so far

Kritti Bhalla

India to begin COVID-19 vaccination for kids aged 12 to 14 from Wednesday

IANS

A Texas pediatrician and professor developed a low-cost COVID-19 vaccine. India just granted it emergency use authorization.

Sarah Al-Arshani

Sun Pharma gets emergency use authorization to manufacture Merck's anti-Covid pill Molnupiravir

IANS

Popular Keywords

Buying Guides